Extended half-life (EHL) recombinant factor VIII drugs promise excellent prophylaxis by reducing dose frequency, enhancing compliance, and improving quality of life while maintaining safety and efficacy. This session will provide a detailed overview of the rationale for developing EHL coagulation factors and their use in the treatment of haemophilia A, with a focus on the indications, efficacy, and safety of the existing EHL-FVIII products.

Emerging role of EHL FVIII in Hemophilia A Mx with better clinical outcomes

Associate Professor and HOD, Department of Pediatric Hematology-Oncology | Post Graduate Institute of Child Health, Noida

This session provides a comprehensive overview of managing inhibitor-positive haemophilia, one of the most challenging complications in haemophilia care. It explores the pathophysiology of inhibitor development, diagnostic strategies, and current treatment approaches, including bypassing agents, immune tolerance induction, and emerging therapies. A clinically focused discussion aimed at improving bleeding control, long-term outcomes, and quality of life in affected patients.

Nita Radhakrishnan

2

206

3.6k

4.5

Upcoming Sessions

Sessions Taken

194

4.5